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Withania Somnifera: Correlation of Phytoconstituents 
with Hypolipidemic and Cardioprotective Activities
Subasini Uthirapathy1 and Tara Fuad Tahir2
Abstract—Withania somnifera (WS) (Dunal) or Ashwagandha is a 
well-known hypolipidemic herb and antioxidant. In this study, 75% 
ethanolic extract of WS is attempted to evaluate the cardioprotective 
activity of isoproterenol-induced cardiotoxicity and hypolipidemic 
activity in Triton WR 1339-induced hyperlipidemia. In addition, 
phytochemical evaluation of the same extracts analyzed by gas 
chromatography–mass spectrometer (GC–MS). This study found 
that 7 days of therapy with WS extracts at 1000 mg/kg b.wt. 
reduced cholesterol by 76%, low-density lipoprotein (LDL) by 
71%, and TAG by 12% (P < 0.05). Furthermore, it can significantly 
reduce cholesterol and LDL levels (P < 0.05). Similarly, the use 
of 50 mg/kg b.wt. of WS extract showed a cardioprotective effect 
against isoproterenol-induced cardiac toxic rats. The antioxidants 
glutathione, glutathione peroxidase, and catalase are increased in 
WS extract (P < 0.05), whereas the release of cardiac indicators in 
heart tissue is reduced (P < 0.05). Furthermore, a 30-day treatment 
with WS also reduced triacylglycerol in isoprenaline-induced 
cardiotoxic rats. GC–MS analysis of the methanol fraction of 
the Ashwagandha 70% ethanolic extract showed the presence of 
higher concentrations of fatty acids. In conclusion, WS showed 
hypolipidemic and cardioprotective activities in diseased animals 
induced by isoproterenol and Triton WR 1339.
Index Terms—Antioxidants, Cardiac markers, Gas 
chromatography–mass spectrometer, Isoproterenol, Lipid, 
Triton WR 1339.
I. Introduction
Withania somnifera (Dunal) (WS) is commonly known as 
winter cherry. It is a green shrub belonging to the Solanaceae 
family. Earlier references have shown that the plant 
preparations have anti-inflammatory (Boehm et al., 2000), 
anti-cancer, anti-stress, and immunomodulatory activities. 
WS has also shown reports of the central nervous system 
(CNS), endocrine (Subasini et al., 2007), and cardiovascular 
(Jasemi et al., 2020) diseases. Furthermore, WS preparations 
are thought to affect GABAergic (gamma-aminobutyric 
acid (GABA) (Dar et al., 2016) or cholinergic (Kumari 
et al., 2020) neurotransmission, which could be associated 
to a variety of CNS disorders. Other plant parts have been 
utilized to treat various diseases for a long time.
The root of WS is the central part of the plant for its 
treatment. WS root powder at 0.75 g and 1.5 g/rodent/day 
can significantly reduce the total cholesterol and triglycerides 
(TGLs) in plasma (Nishant and Narasimhacharya, 2006). Then, 
a considerable increase in plasma high-density lipoprotein 
(HDL) cholesterol levels, the action of 3-Hydroxy-3-Methyl-
Glutaryl-CoA reductase (HMG-CoA) and liver bile acids was 
observed in these rats. A similar pattern was also observed 
in the excretion of bile acids, cholesterol, and neutral sterols 
in hypercholesterolemic rats with oral administration of WS. 
Further, a significant decrease in lipid-peroxidation occurred 
in WS administered hypercholesterolemia animals when 
compared to their normal group of rats. However, it gives an 
idea that WS root extract is also attractive for lowering the 
lipid profile (Saggam et al., 2021).
II. Materials and Methods
A. Chemicals and Reagents
Isoproterenol, malondialdehyde, 1,1’-diphyenyl-2-
picrylhydrazyl, and 2,2’-azinobis-(3-ethyl-benzothiazoline-
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It is familiar that WS has the ability to control oxidative stress 
markers in the body. Conclusively, the root extract decreases 
lipid peroxidation and boosts superoxide dismutase (SOD) and 
catalase activity (Adams et al., 2002). As a result, it has free 
radical scavenging activity. Furthermore, the hypolipidemic 
(Nishant and Narasimhacharya, 2006) and antioxidant activity 
of WS has been demonstrated by Priscilla and Prince, 2009. 
We attempted to assess the cardioprotective impact, as well 
as hypolipidemic and antioxidant activities, in isoproterenol-
induced cardiotoxicity and Triton WR 1339-induced 
hyperlipidemia in this research. To correlate the pharmacological 
activity with its active constituents, gas chromatography–mass 
spectrometer (GC–MS) analysis also carried out.
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6-sulfonic acid) were purchased from Sigma Chemical 
Co., St. Louis, MO, USA. Biochemical kits for the assay 
of cholesterol, TGLs, and HDL cholesterol were procured 
from Randox Laboratories. Creatine kinase (CK)-MB assay 
kit was purchased from SPINREACT. All the other reagents 
used were of analytical grade.
B. Collection and Identification of Plants
The root of WS was obtained from Madurai. The plant 
material was identified in the Department of Pharmacognosy, 
Centre for Advanced Research of the Indian System 
Medicine, SASTRA University, Thanjavur, Tamil Nadu, 
India. The voucher is saved in the same department, 
document number (0064).
C. Preparation of Extract
The collected plant material was dried for 15 days a room 
temperature. The raw materials were grinded to use it for 
extraction with 70% ethanol and the cold infiltration method 
was used.
Vacuum rotary evaporator was used to concentrate the 
extract 40°C. Refrigeration was used to store the concentrated 
extract of 3.83% as the extract yield.
D. Experimental animals
Male Wistar albino rats weighing 180–220 g were allowed 
to have standard pellets from Hindustan Lever Foods, 
Bengaluru, India, and water ad libitum. They are placed 
under normal environmental conditions. All rats experiments 
were performed after obtaining animal ethics approval 
(Authorization No. 7/SASTRA/IAEC/RPP).
E. Hypolipidemic Activity (Acute Model)
Triton WR 1339 is a non-ionic detergent which has been 
used to induce hyperlipidemia in animals. Animals were divided 
into five groups of six rats each. Group 1 animals considered 
as normal and were fed with standard diet. Group 2 animals 
received Triton WR 1339. Group 3 animals were pre-treated 
with atorvastatin 10 mg/kg b.wt./day (p.o.) for 7 days. Groups 4 
and 5 animals were pre-treated with WS at the doses of 500 
and 1000 mg/kg/day (p.o.), respectively, for 7 days. During 
treatment, on the 5th day, 1 h after the administration of that 
samples, all animals except Group 5 were injected with Triton 
WR 1339, intraperitoneally (i.p.) (dissolved in saline) at the 
single dose of 400 mg/kg b.wt. The animals were fasted for 3 h 
before administration of Triton WR 1339 and the fasting was 
continued up to 48 h after administration of Triton WR-1339. 
All animals were fed with water after the injection of Triton 
WR 1339 (Majithiya et al., 2004). The blood was collected 
from all animals before and after 48 h the administration of 
Triton WR 1339 by retro-orbital puncture under volatile (ether) 
anesthesia. Plasma total cholesterol, TGL, and low-density 
lipoprotein (LDL) by Subasini et al., 2019b, were analyzed.
F. Cardioprotective Activity (Chronic Model)
The experimental animals were divided into four groups, 
with six animals in each group. For the first group, normal 
rats were given only a standard diet. Group 2 animals received 
isoproterenol (ISO). Group 3 animals were pretreated with 
WS at a dose of 50 mg/kg body weight for 30 days without 
ISO. Group 4 animals were pretreated with WS 50 mg/
kg body weight for 30 days with ISO. On days 31 and 32, 
animals in Groups 2 and 4 were injected with ISO 85 mg/kg 
body weight subcutaneously (s.c.) for 2 days. At the end of 
the study, the animals were sacrificed by cervical dislocation. 
Blood was collected and then plasma was separated. Heart 
tissue was removed immediately and washed thoroughly with 
saline. The cardiac tissue homogenate was prepared in 0.1 M 
Tris buffer (pH 7.4).
Various biochemical parameters like Creatine Kinase (CK) 
(Ohkawa et al., 2004), Lactate dehydrogenase (LDH) (King, 
1959), Glutamate Pyruvate transaminase (GPT) (Mohun and 
Cook, 1957), Glutamate Oxaloacetate transaminase (GOT) 
(Paglia and Valentine, 1967), Thiobarbituric acid Reactive 
Substances (TBARS) (Ohkawa et al., 2004), Reduced 
Glutathione (GSH) (Moron et al., 1979), Catalase (Aebi, 
1974) were estimated. The plasma concentration of total 
cholesterol and HDL cholesterol (HDLC) was determined 
using an enzyme kit from Randox Laboratories Ltd., UK 
(Richmond, 1973). First, HDLC was determined after 
precipitation of lipoproteins containing apolipoprotein B 
with dextran sulfate (Warnick et al., 1992). Next, the plasma 
TGL concentration and homogenate of heart triacylglycerol 
(TAG) concentration were analyzed by Foster (Foster and 
Dunn, 1973). Finally, the Friedewald equation (Friedewald et 
al., 1972) is used to determine the LDL cholesterol (LDLC) 
concentration.
G. GC–MS Analysis
Ten milligrams of WS extract were dissolved in methanol. 
The methanol fraction separated from the 75% ethanol 
extract was injected for GC–MS analysis. The following 
experimental conditions to analyze the samples by GC–
MS were applied on the PerkinElmer Clarus 500 GC: 
Elite 5 column (5% biphenyl 95% dimethylpolysiloxane), 
column size 30 m × 0.32 mm, gas loading – 1 ml/min of 
helium, column temperature from 50°C to 285°C, a speed 
of 10°C/min for 5 min, at 285°C, the temperature of the 
injector, and the detector was 290°C, and the sample is 
injected split mode, injection volume: 0.5 µl (2 mg/100 ml 
methanol solution). The total run time was 30 min. Mass 
spectra were acquired using a PerkinElmer-TurboMass Gold 
Mass Detector. Transfer line temperature – 230 °C, Source 
temperature – 230 °C, scan range is from 40 – 450 amu, 
ionization technique – Electron ionization technique. The 
component identification was confirmed by comparing mass 
spectra of compounds with available NIST and Willey mass 
spectral library. The quantitative composition was obtained 
by normalizing the peak area (Subasini et al., 2019b).
H. Statistical Analysis
The results are given Mean ±SD, and statistical significance 
is determined using a one-way analysis of variance using the 
Duncan’s multiple range test. A difference of P < 0.05 was 
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considered significant and the SPSS software (version 12.0) 
was used for statistical analysis.
III. Results
A. Effect of WS on Triton WR 1339-Induced 
Hyperlipidemia
Table I shows the results of significant increasing of 
cholesterol, LDL, and TAG levels (P < 0.05) in the rats with 
Triton WR 1339 administration compared to normal rats. 
Rats pretreated with extract at 500 mg/kg b.wt. showed no 
significant hypolipidemic activity, but rats pre-treated with 
extract at 1000 mg/kg b.wt. for 7 days showed a reduction in 
cholesterol levels and LDL against a diseased group of rats. 
Treatment with atorvastatin reduced cholesterol and LDL 
levels significantly (P < 0.05) without changing TAG levels.
B. Effect of WS on Isoproterenol-induced Cardiotoxicity
Isoproterenol administration was observed to raise 
cholesterol, LDL significantly, and TAG levels in serum while 
decreasing HDL levels (P < 0.05). Treatment of rats with WS 
extract did not reverse substantially normal cholesterol, LDL, 
and HDL levels. At a dose of 50 mg/kg b.wt, pre-treating rats 
with WS extract for 30 days can dramatically reduce TAG 
levels (P < 0.05) in Table II. The level of cardiac markers 
was considerably higher in the serum of diseased animals and 
lowered in the heart homogenate (P < 0.05). The discharge 
of cardiac markers was observed to be dramatically reduced 
(P < 0.05) when rats were pre-treated with the extract and the 
findings are summarized in Table III. In the same way, the 
amount of TBARS was higher, and the level of antioxidants 
was found to be lower in the serum and heart homogenate 
of the diseased group of rats. Pre-treating animals with 
WS extract can considerably improve antioxidant levels 
(P < 0.05), reduce membrane damage, and reduce the release 
of TBARS which are shown in Table IV.
C. GC–MS Analysis of WS Extract
GC–MS analysis showed octadecadienoic acid methyl 
ester and hexadecadienoic acid ethyl ester as the primary 
compound. It was followed by glycerine, sucrose, and 4H, 
1,2,4-Triazol-3-amine-4-propyl as the primary compound in 
Fig. 1. Other chemical compounds are mentioned in Table V.
IV. Discussion
The HMG-CoA reductase activity has been 
reported to have decreased by root powder of WS 
(Nishant and Narasimhacharya, 2006) at the dose of 
750 mg/kg b.wt./day/rat. To evaluate the effect of WS’s 
70% ethanolic extract, we have selected two different 
doses with 750 mg/kg/b.wt. as the middle dose. Nishant 
and Narasimhacharya (2006) have administered drug 
for 4 weeks. In our present study, we have attempted to 
evaluate the effect of extract for a shorter duration. Thus 
for our current study, we have administered extract only 
for 7 days and compared the same with the effect of the 
standard drug atorvastatin. Peer et al., 2008, have adopted 
the diet-induced hyperlipidemia method, whose mechanism 
of action increases HMG-CoA reductase activity. We have 
also planned to select a hyperlipidemic model related to the 
activity of that enzyme. Triton WR 1339 is a surfactant that 
can induce hyperlipidemic conditions by increasing HMG-
CoA reductase activity (Badavi et al., 2020). Moreover, 
Triton WR 1339 is a widely accepted model for evaluating 
the effect of hypolipidemic herb (Ipseeta et al., 2004).
The activity of WS extract at 1000 mg/kg b.wt. in Triton 
WR 1339 caused hyperlipidemic rat is comparable to that of 
the commercially available standard medication atorvastatin. 
Atorvastatin treatment was observed to significantly decrease 
cholesterol and LDL (P < 0.05) without effect on TAG. 
Since the Triton WR 1339 increases the activity of HMG-
CoA reductase, the decrement observed in atorvastatin 
treatment might be due to decreasing the activity of HMG-
CoA reductase (Youssef et al., 2002). A comparable activity 
followed by WS treatment shows that the WS extract 
inhibits HMG-CoA reductase. It was observed a reduction 
in HMG-CoA reductase activity (Subasini et al., 2014). The 
hypolipidemic activity of WS might be due to the presence 
of polyunsaturated fatty acids in chromatogram GC–MS of 
the chemical compounds of WS extract (Minihane et al., 
2005). Isoproterenol-induced cardiotoxic model is adopted 
Table I
Effect Of Ws Extract And Atorvastatin In Triton Wr 1339-Induced 
Hyperlipidemic Rats






1 Normal rats 63.5±5.3 40.2±10.5 53.8±10.6




4 Triton WR 1339+WS 
(500 mg/kg b.wt.)
754.9±28.3ns 580.5±32.5ns 562.5±23.9ns
5 Triton WR 1339+WS 
(1000 mg/kg b.wt.)
665.3±19.5a 479.4±19.8a 525.0±14.4ns
Values are Mean±SD. n=6. Statistical difference is calculated in one-way ANOVA (LSD) 
method (least significant difference). *Statistical difference between Group 1 and 2 (P<0.05). 
aSignificant difference between Groups 3, 4, and 5 versus Group 2 (P<0.05). ns – No 
significant difference between specific groups versus Group 2. LDL and  
TAG: Triacylglycerol, LDL: Low-density lipoprotein
Table II
Effect Of Ws Extract On Lipid Profile In Isoproternol-Induced 
Cardiotoxic Rats








1 Normal 74.10±4.1 20.30±0.7 40.40±1.2 66.80±4.6
2 ISO 95.20±2.7* 14.80±0.4* 62.80±1.3* 87.80±2.3*
3 WS 
(50 mg/kg b.wt.)
77.30±2.4€ 19.70±0.9€ 44.30±2.3€ 66.50±5.1€
4 ISO+WS 
(50 mg/kg b.wt.)
86.60±1.7ns 16.30±0.7ns 58.04±2.3ns 61.30±8.9a
Values are Mean±SD. n=6. Statistical difference is calculated in one-way ANOVA 
method (least significant difference). *Statistical difference between Groups 1 and 
2 (P<0.05). € – No significant difference between Group 1 versus Group 3. ns – No 
significant difference between Group 1 versus Group 4. aSignificant difference (P<0.05) 
between Group 1 versus Group 4. HDL: High-density lipoprotein, LDL: Low-density 
lipoprotein, TAG: Triacylglycerol
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for the present research. The main purpose of selecting this 
model is to evaluate the myocardial membrane stabilizing 
effect through antioxidant and hypolipidemic activity of WS’s 
70% ethanolic extract. Minihane (Minihane et al., 2005) has 
also suggested that isoproterenol-induced cardiotoxicity is a 
widely accepted non-invasive model.
The primary purpose of selecting this model is to 
evaluate the myocardial membrane-stabilizing effect through 
antioxidant and hypolipidemic activity of WS’s 70% 
ethanolic extract. Isoproterenol-induced cardiotoxicity has 
been suggested as it is a widely accepted non-invasive mode 
(Arnaldo et al., 2004). The modulation of oxidative stress 
by WS root powder has been reported earlier (Saleem et al., 
2020). Isoproterenol causes ischemia or oxidative stress but 
also causes positive inotropic and chronotropic effects on 
the heart (Fontana et al., 2007). These abnormal conditions 
lead to the damage of the heart. The deterioration in the 
heart tissue results in the release of cardiac markers and lipid 
accumulation in the myocardium (Subasini et al., 2009a). 
The myocardial membrane can be protected from damage 
induced by isoproterenol’s hazardous nature by a medication 
having antioxidant action.
A drug that can act as an antioxidant and as a receptor 
antagonist can prevent the binding of isoproterenol with its 
receptor and thereby protect the heart from the toxic effect 
of isoproterenol. Reactive oxygen species are produced 
Table  IV
Effect Of Ws On Antioxidants In Isoproternol-Induced Cardiotoxicity
Sample Parameter Normal ISO WS ISO+WS
Plasma TBARS 0.08±0.0005 0.17±0.0002* 0.08±0.0400€ 0.11±0.0100a
GSH 4.60±0.0190 2.60±0.0800* 4.20±0.0250€ 4.00±0.0400a
GPX 3.60±0.0600 2.70±0.1000* 3.80±0.0400€ 3.60±0.0500a
Heart TBARS 0.62±0.0007 0.92±0.0011* 0.64±0.0600€ 0.73±0.0100a
GSH 124.60±6.0000 83.60±2.5000* 127.30±11.0000€ 102.60±1.7000a
GPX 3.40±0.0800 2.20±0.0400* 3.20±0.0200€ 4.10±0.0900a
Catalase 0.50±0.0070 0.20±0.0080* 0.50±0.0100€ 0.50±0.0500a
Values are Mean±SD. n=6. Statistical difference is calculated in one-way ANOVA method (least significant difference). *Statistical difference between Groups 1 and 2 (P<0.05). 
€ – No significant difference between Group 1 versus Group 3. aSignificant difference (P<0.05) between Group 1 versus Group 4. One nMol of MDA/mg of protein, 2 µg of GSH/
mg of protein, 3 µg of GSH used/min/mg of protein, 4 µMol of H2O2 used/min/mg of protein. TBARS: “Thiobarbituric acid reactive substance,” GSH: “Reduced glutathione,” GPX: 
Glutathione peroxidase
Table III
Effect Of Ws On Cardiac Markers In Isoproternol-Induced Cardiotoxicity
Sample Parameter Normal ISO WS ISO+WS
Plasma CK 4.500±0.0300 8.300±0.0300* 4.400±0.0200€ 5.800±0.0900
LDH 0.200±0.0040 0.440±0.0300* 0.240±0.0200€ 0.290±0.0070a
GOT 0.050±0.0003 0.080±0.0900* 0.050±0.0200€ 0.062±0.0009a
GPT 0.030±0.0009 0.130±0.5000* 0.040±0.0100€ 0.050±0.0040a
Heart CK 236.900±4.4000 174.500±3.3000* 239.000±13.0000€ 228.800±5.9000a
LDH 2.700±0.0400 1.400±0.0600* 2.600±0.0200€ 2.700±0.0900a
GOT 2.300±0.0300 1.400±0.0170* 2.400±0.0160€ 2.400±0.0900a
GPT 2.700±0.0600 1.500±0.0300* 2.600±0.0100€ 2.900±0.0600a
Values are Mean±SD. n=6. Statistical difference is calculated in one-way ANOVA method (least significant difference). *Statistical difference between Groups 1 and 2 (P<0.05). € – No 
significant difference between Group 1 versus Group 3; asignificant difference (P<0.05) between Group 1 versus Group 4. One micrograms of phosphorous liberated/min/mg of protein, 
2 µg of pyruvate liberated/min/mg of protein. CK: “Creatine kinase,” LDH: Lactate dehydrogenase,” GOT: “Glutamate oxaloacetate aminotransferase,” GPT: “Glutamate pyruvate 
transaminase”
Fig. 1. Chromatogram gas chromatography–mass spectrometer of the chemical compounds of WS extract.
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by a variety of mechanisms including xanthine oxidase, 
nicotinamide adenine dinucleotide phosphate oxidases, 
cytochrome P450, catecholamine auto-oxidation, and nitric 
oxide (NO) synthase uncoupling NO synthases. Isoproterenol 
(ISO), a synthetic catecholamine, undergoes oxidation and 
generates superoxide anion. The superoxide radical initiates 
the chain reactions and results in free radical intermediates 
and lipid peroxidation. Drugs with antioxidant qualities may 
supplement endogenous defense systems and lower both the 
initiation and propagation of the lipid peroxidation process 
(Thenmozhi and Subasini, 2016). The decreased TBARS and 
increased activity of antioxidants observed in the present 
study might be due to the presence of withanolides (Peer 
et al., 2008). According to Badavi et al., 2020, ISO causes 
myocardial infarction in experimental animals by acting on 
the sarcoplasmic membrane, stimulating adenylate cyclase, 
activating Na+ and Ca2+ channels, and causing myocardium 
cell death. The elevated level of marker enzymes in serum 
may be due to the harm induced by these impacts (Subasini, 
2009a). CK level is increased significantly (P < 0.05) in 
serum of diseased rats against normal rats. The results are 
in line with an earlier reference (Vimal and Devaki, 2004). 
The decreased level of LDH in heart tissue of diseased rats 
is in line with a previous referred reference (Saravanan et al., 
2011). The reduced activity of LDH prevents the conversion 
of lactate to pyruvate. As mentioned above, ischemia 
increases anaerobic glycolysis.
Similarly, the GPT level considerably reduces the 
cardiac tissue of diseased group of rats. In experimental 
inflammatory circumstances, Priscilla (Priscilla and 
Prince, 2009) discovered that enzymatic tissue activities, 
particularly aminotransferases, increased. The WS extract’s 
mechanism may work by lowering Ca2+ inflow and avoiding 
enzyme leakage by reducing myocardial damage. Still, the 
mechanism of the protective action of this extract should be 
evaluated. The decreased release of cardiac markers by WS 
pre-treatment might be due to various antioxidant activity 
exhibiting compounds like withanolides (Durg et al., 2015).
Ipseeta et al., 2004, have shown that the WS treatment 
can prevent the influx of calcium, negative inotropic and 
chronotropic activity. Moreover, Gupta (Gupta et al., 2004) 
has explained that ISO causes increased myocardial lipids. It 
raises LDL cholesterol levels in the blood, causing dangerous 
deposits to form in the arteries and so favoring coronary 
heart disease.
In addition, ISO promotes lipolysis in the myocardium 
(Jasemi et al., 2020, and Ipseeta et al., 2004). Lipolysis 
results in the release of a large amount of free fatty acids and 
TAG. The decrement of TAG observed in our present study 
reveals that WS extract is exhibiting membrane stabilizing 
activity (Subasini et al., 2009b). GC–MS analysis of 
methanol-soluble volatile compounds of WS’s 70% ethanolic 
extract has indicated fatty acids such as octadecadienoic 
acid, methyl ester, and hexadecadienoic acid ethyl ester. The 
hexadecadienoic acid-ethyl ester with a peak area of 24.27% 
is present in higher concentrations. The cardioprotective 
activity of this compound has not been reported earlier. 
The observed cardioprotective activity in the present study 
might be due to the presence of octadecadienoic acid, methyl 
ester, hexadecadienoic acid ethyl ester, and hexadecadienoic 
acid-ethyl ester. The action might be due to the synergistic 
action of all the mentioned above compounds. The extract 
contains sucrose and sucrose administration can induce 
lipid peroxidation and decrease Cu-Zn SOD (Jerome et al., 
2002). The observed antioxidant activity might be due to 
the presence of other compounds like fatty acids, which are 
present in higher concentrations (peak area = 23.57%) than 
that of sucrose (peak area = 9.12%) (Subasini et al., 2007).
V. Conclusion
In Triton WR 1339 generated hyperlipidemic rats, WS has 
hypolipidemic action by lowering cholesterol and LDL levels. 
Similarly, WS extract administration decreases cardiotoxicity 
in isoproterenol-induced cardiotoxic rats through boosting 
antioxidant levels. Increased antioxidants also reduce TBARS 
release and cardiac marker release from cardiac tissue. 
Moreover, the WS extract also reduces the level of TAG 
in the plasma of isoproterenol administered in rats. The 
presence of fatty acids detected by the GC–MS spectrum is 
responsible for the extract’s hypolipidemic, cardioprotective, 
and antioxidant activities.
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